"As a result most Asian countries are forced to buy from the fractionators and discard the plasma they collect. Significantly, every 50,000L of currently Unprocessable Plasma can generate over US$30m of Therapeutic Plasma products."
"This is the unique niche that the PrIME process addresses and on average this Currently Unprocessable Plasma will generate $30m of sales and $15M of annual profit per country."
The PrIME technology is a disposable, scalable manufacturing process through its modular separation cartridge. The system can process any volume from 20L to 1,000,000L.
At 1,000,000L, annual profit is $300 million. NSP's target within 5-7 years!
Country Potential Market Size
Singapore $100M
Thailand $1.2B
Philippines $1.6B
Malaysia $470M
Singapore alone already provides the opportunity for NSP to grow 10 baggers to move into ASX 300.
The PrIME technology is a disposable, scalable manufacturing process through its modular separation cartridge. The system can process any volume from 20L to 1,000,000L.
The PrIME plasma process offers a number of advantages over the existing plasma fractionation processes. The existing processes are mostly built on the original Cohn fractionation process which dates back to WWII. The introduction of column chromatology late last century contributed to increased selectivity and the improved ability to reduce viral contamination. The current fractionation process, however, can be cumbersome and not modular and requires long periods of down time because of vigorous clean in place regimes to ensure safety in the system.
MEM Price at posting:
7.3¢ Sentiment: LT Buy Disclosure: Held
